This Dividend Anchor Could Return More Than 23% In 2017

Pfizer has been on a roll lately, recently announcing successful top-line results for its third biosimilar in the last four months. The success of its biosimilar initiatives could potentially give Pfizer a secure foothold in the biosimilars market, which could grow to $20 billion in just three years.

Press release distribution, EDGAR filing, XBRL, regulatory filings

Pfizer Receives Approval in the European Union for Nimenrix in Infants Six Weeks of Age and Older )–Pfizer Inc. announced today the European Commission has approved an expanded indication for Nimenrixa Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express High Levels of PD-L1 )–KEYTRUDA Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express H… )–Madame Tussauds and country superstar Brad Paisley joined forces to pay tribute to Grand Ole Opry legend Little Jimmy Dickens by unveiling his wax figure on the R… )–Manitowoc Foodservice announces SVP, General Counsel and Secretary Maurice Jones retirement; promotes Joel Horn to SVP, General Counsel and Secretary effecti… )–Mitsubishi UFJ Capital, a … (more)